In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
NEW YORK (Reuters Health) – Adding cetuximab to standard chemotherapy for colorectal liver metastases often shrinks inoperable lesions enough to permit resection, according to a study released today…
NEW YORK (Reuters Health) – Systolic blood pressure, left ventricular (LV) mass, and diabetes status independently predict the likelihood that prehypertensive patients with cardiac risk factors will develop…
NEW YORK (Reuters Health) – Transradial percutaneous coronary intervention (PCI) for acute MI is associated with a lower risk of major bleeding and other adverse events than transfemoral…
NEW YORK (Reuters Health) – Treating HER-2 positive, metastatic breast cancer with trastuzumab significantly increased survival in a retrospective study, to the point were such women given the…
NEW YORK (Reuters Health) – In patients receiving glucocorticoids for inflammatory diseases, adverse events are very common, even at low to medium doses, according to a meta-analysis by…
NEW YORK (Reuters Health) – Interruption of cardiopulmonary resuscitation (CPR) compressions is common and prolonged when paramedics attempt to perform endotracheal intubation at the same time, research indicates.…
Patrick Conway, MD, MSc, Chief Medical Officer Policy Division for the Secretary of Health and Human Services, Executive Director Federal Coordinating Council for Comparative-Effectiveness Research at Health and…
Patrick Conway, MD, MSc, Chief Medical Officer Policy Division for the Secretary of Health and Human Services, Executive Director Federal Coordinating Council for Comparative-Effectiveness Research at Health and…
Robert Shorr, Ph.D, D.I.C, CEO, Cornerstone Pharmaceuticals, discusses how physicians can understand a new oncology drug, starting with knowing its safety limitations. He also explains the structure and…
